Toripalimab
Coherus,Junshi Biosciences
['lung', 'lcsm,(-blcsm)', 'toripalimab', 'ts,perio,i', 'nsclc', 'sclc']
perioperative toripalimab plus chemotherapy improves event-free survival over chemotherapy alone in stage iii non-small cell lung cancer, a phase 3 study presented at asco 2023 suggests. #asco23 #lcsm #nsclc 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.